JP7055754B2 - 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法 - Google Patents

角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法 Download PDF

Info

Publication number
JP7055754B2
JP7055754B2 JP2018554642A JP2018554642A JP7055754B2 JP 7055754 B2 JP7055754 B2 JP 7055754B2 JP 2018554642 A JP2018554642 A JP 2018554642A JP 2018554642 A JP2018554642 A JP 2018554642A JP 7055754 B2 JP7055754 B2 JP 7055754B2
Authority
JP
Japan
Prior art keywords
gel composition
item
composition
weight
stable gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018554642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019505583A5 (cg-RX-API-DMAC7.html
JP2019505583A (ja
Inventor
ウィリアム ボローニャ,
フィン ラーセン,
Original Assignee
ヴィラマル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィラマル リミテッド filed Critical ヴィラマル リミテッド
Publication of JP2019505583A publication Critical patent/JP2019505583A/ja
Publication of JP2019505583A5 publication Critical patent/JP2019505583A5/ja
Priority to JP2022063361A priority Critical patent/JP2022088646A/ja
Application granted granted Critical
Publication of JP7055754B2 publication Critical patent/JP7055754B2/ja
Priority to JP2024062228A priority patent/JP2024083507A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018554642A 2016-01-07 2017-01-06 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法 Active JP7055754B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022063361A JP2022088646A (ja) 2016-01-07 2022-04-06 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法
JP2024062228A JP2024083507A (ja) 2016-01-07 2024-04-08 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662275955P 2016-01-07 2016-01-07
US62/275,955 2016-01-07
US201662371670P 2016-08-05 2016-08-05
US62/371,670 2016-08-05
PCT/US2017/012564 WO2017120492A1 (en) 2016-01-07 2017-01-06 Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022063361A Division JP2022088646A (ja) 2016-01-07 2022-04-06 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2019505583A JP2019505583A (ja) 2019-02-28
JP2019505583A5 JP2019505583A5 (cg-RX-API-DMAC7.html) 2020-02-20
JP7055754B2 true JP7055754B2 (ja) 2022-04-18

Family

ID=58463817

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018554642A Active JP7055754B2 (ja) 2016-01-07 2017-01-06 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法
JP2022063361A Pending JP2022088646A (ja) 2016-01-07 2022-04-06 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法
JP2024062228A Pending JP2024083507A (ja) 2016-01-07 2024-04-08 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022063361A Pending JP2022088646A (ja) 2016-01-07 2022-04-06 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法
JP2024062228A Pending JP2024083507A (ja) 2016-01-07 2024-04-08 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法

Country Status (11)

Country Link
US (2) US20170196896A1 (cg-RX-API-DMAC7.html)
EP (2) EP4091601A1 (cg-RX-API-DMAC7.html)
JP (3) JP7055754B2 (cg-RX-API-DMAC7.html)
CN (1) CN108712901A (cg-RX-API-DMAC7.html)
AU (2) AU2017206048B2 (cg-RX-API-DMAC7.html)
CA (1) CA3010829A1 (cg-RX-API-DMAC7.html)
ES (1) ES2949053T3 (cg-RX-API-DMAC7.html)
GB (1) GB2551598B (cg-RX-API-DMAC7.html)
IL (2) IL300437B1 (cg-RX-API-DMAC7.html)
MX (2) MX393613B (cg-RX-API-DMAC7.html)
WO (1) WO2017120492A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11007144B2 (en) 2016-11-15 2021-05-18 Klaria Pharma Holding Ab Pharmaceutical formulation
GB201709141D0 (en) 2017-06-08 2017-07-26 Klaria Pharma Holding Ab Pharmaceutical formulation
IL271596B2 (en) * 2017-06-22 2024-07-01 Viramal Ltd Emulsion compositions comprising danazol for use in the treatment of an endometrial disease or condition
WO2019093780A1 (ko) * 2017-11-10 2019-05-16 (주)아모레퍼시픽 바이겔 타입의 화장료 조성물
CN108635330B (zh) * 2018-04-17 2021-11-30 上海普特生物科技有限公司 一种长效缓释黄体酮凝胶剂组合物
GB201808462D0 (en) 2018-05-23 2018-07-11 Klaria Pharma Holding Ab Pharmaceutical formulation
PL3829551T3 (pl) * 2018-07-30 2024-04-02 Biothea Pharma, Inc. Krystaliczna sól malonianu epinefryny
AU2019365255B2 (en) * 2018-10-26 2025-06-12 Viramal Limited Mucoadhesive gel composition
EP3659583B1 (en) * 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
EP3922235A1 (en) * 2020-06-11 2021-12-15 Viramal Limited A hydroalcoholic gel and a method of manufacturing said gel
US20240315996A1 (en) * 2021-02-02 2024-09-26 DuPont Nutrition USA, Inc. An aqueous gel composition comprising an ethylcellulose
CN112970804A (zh) * 2021-03-29 2021-06-18 陕西农产品加工技术研究院 一种基于甘油二酯油凝胶的枸杞面包及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528864A (ja) 2003-07-16 2007-10-18 イタルファルマコ,ソシエダ アノニマ 半固体粘膜接着製剤
JP2010514748A (ja) 2006-12-29 2010-05-06 アーダナ バイオサイエンス リミテッド 組成物の調製方法
JP2013540698A (ja) 2010-08-09 2013-11-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Hiv−1感染の処置のための方法及び医薬的組成物
JP2014513716A (ja) 2011-05-15 2014-06-05 トリメル バイオファーマ エスアールエル 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US618323A (en) 1899-01-24 Berndt e
FR2739559B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Gel pour hormonotherapie locale de la secheresse vaginale
DE69919863T8 (de) * 1998-06-03 2005-12-15 Ardana Bioscience Ltd. Stabilgelmischung in form einer mischung eines öligen gels und eines wässrigen gels
FR2779438B1 (fr) * 1998-06-03 2004-12-24 Jean Marc Aiache Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
US6743448B2 (en) * 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
CA2601969A1 (en) * 2005-02-10 2006-08-17 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
DE102005037844A1 (de) * 2005-08-04 2007-04-05 Intendis Gmbh Wasserfreies Mehr-Phasen-Gel-System
US8475774B2 (en) 2010-02-08 2013-07-02 Johnson & Johnson Consumer Companies, Inc. Sunscreen compositions comprising an ultraviolet radiation-absorbing polymer
US11154535B2 (en) * 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
WO2014026707A1 (en) * 2012-08-13 2014-02-20 Edko Pazarlama Tanitim Ticaret Limited Sirketi Anti-vaginitis compositions with improved release and adherence

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528864A (ja) 2003-07-16 2007-10-18 イタルファルマコ,ソシエダ アノニマ 半固体粘膜接着製剤
JP2010514748A (ja) 2006-12-29 2010-05-06 アーダナ バイオサイエンス リミテッド 組成物の調製方法
JP2013540698A (ja) 2010-08-09 2013-11-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Hiv−1感染の処置のための方法及び医薬的組成物
JP2014513716A (ja) 2011-05-15 2014-06-05 トリメル バイオファーマ エスアールエル 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Drug Delivery System,2009年,Vol.24-4,p.384-393

Also Published As

Publication number Publication date
AU2017206048B2 (en) 2023-04-13
EP3399963B1 (en) 2023-06-07
EP3399963C0 (en) 2023-06-07
CA3010829A1 (en) 2017-07-13
ES2949053T3 (es) 2023-09-25
MX393613B (es) 2025-03-24
BR112018013979A2 (en) 2018-12-11
KR20180117103A (ko) 2018-10-26
AU2023201712B2 (en) 2025-07-31
JP2022088646A (ja) 2022-06-14
GB201700220D0 (en) 2017-02-22
IL300437A (en) 2023-04-01
IL300437B1 (en) 2026-06-01
CN108712901A (zh) 2018-10-26
IL260462A (cg-RX-API-DMAC7.html) 2018-08-30
MX2022008277A (es) 2022-08-04
EP3399963A1 (en) 2018-11-14
US20210338693A1 (en) 2021-11-04
IL260462B2 (en) 2023-07-01
WO2017120492A1 (en) 2017-07-13
AU2023201712A1 (en) 2023-04-20
EP3399963A4 (en) 2019-09-04
AU2017206048A1 (en) 2018-08-16
GB2551598B (en) 2022-03-09
MX2018008467A (es) 2019-01-10
IL260462B1 (en) 2023-03-01
JP2024083507A (ja) 2024-06-21
US20170196896A1 (en) 2017-07-13
JP2019505583A (ja) 2019-02-28
EP4091601A1 (en) 2022-11-23
BR122023025444A2 (pt) 2024-02-20
GB2551598A (en) 2017-12-27

Similar Documents

Publication Publication Date Title
JP2022088646A (ja) 角質層および血清中の薬物濃度を最大にするための経皮送達用ゲル組成物ならびにそれを使用する方法
JP4825305B2 (ja) 経皮吸収製剤
ES2945590T3 (es) Composiciones farmacéuticas transdérmicas que comprenden agentes activos
CN103327962B (zh) 睾酮制剂
JP2002512600A (ja) 経皮治療製剤
JP2019505583A5 (cg-RX-API-DMAC7.html)
CA2731501C (en) Transdermal pharmaceutical compositions comprising danazol
HK40083904A (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
HK1263012A1 (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
BR122024008916A2 (pt) Composições em gel estável e seu método de preparo
CZ304915B6 (cs) Využití alaptidu jako modifikátoru transdermální penetrace ve farmaceutických kompozicích pro humánní a veterinární aplikace obsahující nesteroidní antiflogistika a/nebo antipyretika-analgetika
BR112018013979B1 (pt) Composições em gel estável e seu método de preparo
BR122023025444B1 (pt) Composição de gel estável, e, método de preparação de uma composição em gel estável
BR122024008916B1 (pt) Composições em gel estável e seu método de preparo
JP2001048783A (ja) 経皮吸収型頻尿・尿失禁治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220131

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220406

R150 Certificate of patent or registration of utility model

Ref document number: 7055754

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250